
Biomedica
Biomedica – The Leading Musculoskeletal Health Brand in the Asia-Pacific
Biomedica is committed to "6 Seconds to A Safer Tomorrow – AIXA Health, Keeping Osteoporosis and Sarcopenia Away." As a pioneer in AI-powered precision medicine, we provide simple and accurate disease screening solutions to safeguard women's health worldwide.
We specialize in developing AI-driven disease screening technologies and offer Illumina NGS automated cancer detection solutions. Our innovations not only enhance comprehensive healthcare but also provide clinicians and researchers with clinical solutions backed by evidence-based medicine.
Rooted in Taiwan and expanding globally, Biomedica has obtained medical certifications and established a presence in 13 countries, continuously driving AI healthcare innovation to shape the future of health management.
AIXA Osteoporosis, Sarcopenia and Fractures Screening
Solution Description
AIXA Osteo is a cutting-edge AI-powered musculoskeletal screening solution designed to assess osteoporosis, sarcopenia, and vertebral compression fractures with speed and accuracy. Utilizing advanced imaging analysis, AIXA supports X-ray and CT scans, providing clinically validated reports to enhance screening efficiency, streamline diagnostic workflows, and enable large-scale health assessments.
1. Beyond DXA Limitations – Enables bone density and sarcopenia assessments using X-ray, increasing accessibility
2. High-Efficiency AI Analysis – Generates clinical reports in just 6 seconds
3. Accurate & Reliable – DXA-standard bone density correlation (R=0.996), with 97.2% sensitivity
4. Versatile Applications – Suitable for hospitals, clinics, long-term care facilities, health check-up centers, and mobile X-ray units
5. Comprehensive Report – Standardized analysis of the spine, hip, and lower limbs, providing a musculoskeletal health assessment
AIXA makes musculoskeletal screening faster, more precise, and more accessible, empowering early intervention and disease prevention!